Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Benitec Biopharma Ltd (NASDAQ:BNTC)

2.94
Delayed Data
As of Dec 12
 0.00 / 0.00%
Today’s Change
1.30
Today|||52-Week Range
5.48
+92.16%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$31.9M

Company Description

Benitec Biopharma Ltd. engages in the development of therapeutics based on patented gene silencing technology called ddRNAi. It develops treatments for chronic and life threatening human conditions, such as oculopharyngeal muscular dystrophy, oncology, wet age-related macular degeneration, and hepatitis B. It operates through the Australia and USA geographical segments. The company was founded by Kenneth C. Reed in 1997 and is headquartered in North Sydney, Australia.

Contact Information

Benitec Biopharma Ltd.
Suite 1201
North Sydney New South Wales (nsw) 2060
P:(129) 555-6986
Investor Relations:

Employees

Shareholders

Mutual fund holders--
Individual stakeholders--
Other institutional--

Top Executives

Gregory C. WestChief Executive Officer & Secretary
Cliff HollowayChief Operating & Business Officer
Bryan DulhuntyChief Financial Officer
David SuhyChief Scientific Officer
Georgina H. KilfoilChief Clinical & Development Operations Officer